TLP
SLNO

Tri Locum Partners’s Soleno Therapeutics SLNO Stock Holding History

Tri Locum Partners’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-450,585
Closed -$30.5M – 22
2025
Q3 		$30.5M Buy
450,585
+161,705
+56% +$12M 7% 9
2025
Q2 		$24.2M Buy
288,880
+53,960
+23% +$4.04M 7.34% 6
2025
Q1 		$16.8M Buy
+234,920
New +$11.4M 8.61% 3

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tri Locum Partners's SLNO Position: Q4 2025 in Review

Tri Locum Partners sold out of Soleno Therapeutics (SLNO) in Q4 2025, closing a stake of 450,585 shares — an estimated $30.5M sold.

Tri Locum Partners first reported a position in SLNO in Q1 2025 and held it in 3 quarters. The position peaked at $30.5M in Q3 2025. 248 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

  • Tri Locum Partners reported no remaining Soleno Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tri Locum Partners sold 450,585 Soleno Therapeutics shares in Q4 2025, an estimated $30.5M.
  • Tri Locum Partners first reported a position in Soleno Therapeutics in Q1 2025 and held it in 3 quarters.
  • Tri Locum Partners's Soleno Therapeutics position peaked at $30.5M in Q3 2025.
  • 248 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on Tri Locum Partners's 13F filing for Q4 2025, filed 17 Feb 2026.